Northern Dynasty Minerals Ltd. (NYSE:NAK) touched its 1-Year High price of $3.45 on 01/24/17 and its 1-Year Low price of $0.54 on 10/13/16.
Looking further at additional technical indicators we can see that the 14-day Commodity Channel Index (CCI) for Valeant Pharmaceuticals Intl (VRX) is sitting at -4.51. The company's 50-day moving average price is $14.02 and its 200 day moving average price is $13.51. As of May 15th, there was short interest totalling 54,171,329 shares, an increase of 10.5% from the April 28th total of 49,024,853 shares. Cloudera Inc (CLDR)'s Williams Percent Range or 14 day Williams %R now sits at -97.49. The company beat the analyst EPS Estimate with the difference of $0.09. Valeant Pharmaceuticals Intl had a negative net margin of 22.17% and a positive return on equity of 43.81%.
The company's stock is now moving with a +ve distance from the 200 day SMA of approximately 15.49%, and has a solid year to date (YTD) performance of -1.93% which means that the stock is constantly adding to its value from the previous fiscal year end price. During the same period in the prior year, the firm earned ($1.08) earnings per share.
Valeant Pharmaceuticals International, Inc. on 6/29/2010 reported its EPS as $0.58 with the analysts projecting the EPS of the stock as $0.49. Moving averages can help spot trends and price reversals. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Schutter Richard U. De bought 20,000 shares of Valeant Pharmaceuticals Intl stock in a transaction dated Thursday, May 11th. Alternately, if the indicator goes below -80, this may point to the stock being oversold. The disclosure for this purchase can be found here. Trading volume for Northern Dynasty Minerals Ltd. was 5.91 Million in its previous trading session.
The 14-day ADX for Valeant Pharmaceuticals Intl Inc (VRX.TO) is now sitting at 13.09.
The stock has Return on Assets (ROA) of -2.6 percent. Janney Montgomery Scott LLC now owns 19,573 shares of the specialty pharmaceutical company's stock worth $216,000 after buying an additional 848 shares during the period. ValueAct Holdings L.P. increased its position in shares of Valeant Pharmaceuticals International by 20.0% during the first quarter. Canada Pension Plan Investment Board now owns 2,104,500 shares of the specialty pharmaceutical company's stock valued at $36,525,000 after acquiring an additional 2,096,100 shares during the period. 1 analysts gave its stock an Outperform rating. Institutional investors own 64.34% of the company's stock. They set an overweight rating and a $18.00 target price for the company. Scotiabank reduced their target price on shares of Valeant Pharmaceuticals Intl from $15.00 to $12.00 and set a "sector perform" rating on the stock in a research note on Wednesday, April 26th. Barclays PLC reissued a "hold" rating and issued a $34.00 target price on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, February 9th. Wells Fargo & Company restated an underperform rating on shares of Valeant Pharmaceuticals International in a research report on Monday, June 12th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Valeant Pharmaceuticals Intl has a consensus rating of "Hold" and a consensus target price of $22.36.
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company.